Guardant Health disclosed that Craig Eagle, the company’s chief medical officer, will resign effective May 8. Eagle previously held oncology medical affairs roles at Genentech (Roche) and leadership positions at Pfizer, bringing decades of translational and regulatory experience to Guardant’s liquid biopsy strategy. In other industry executive updates, Delfi Diagnostics appointed Charles Newton to its board, with prior CFO experience at Lyell Immunopharma. Singular Genomics named John Stark as its new CEO, replacing a transition plan that brings current CEO Josh Stahl into an independent director role. The reshuffles highlight the ongoing emphasis on leadership continuity across oncology diagnostics and genomics platforms as commercialization, evidence generation, and reimbursement pressure intensify.